Monte Rosa Net Loss Widens as R&D Spending Increases
The biotechnology company reported a net loss of $43.4 million for the second quarter.
Monte Rosa Therapeutics (GLUE), the biotechnology company, reported a widened net loss for the second quarter.
The company experienced a sharp increase in quarterly losses driven by a combination of declining collaboration revenue and higher spending on clinical programs.
Net loss reached $43.4 million, compared to a net loss of $12.3 million in the same period last year. Collaboration revenue fell to $9.0 million from $23.2 million a year earlier.
Operating expenses rose as the company scaled its clinical efforts. Research and development expenses increased to $48.0 million from $30.7 million in the prior-year quarter, primarily due to increased spending on the MRT-8102 program. General and administrative expenses also rose to $10.1 million from $8.1 million.
Clinical milestones progressed across several programs. The company activated the MODeFIRe-1 Phase 2 study of MRT-2359 in combination with apalutamide, moving the timeline up from the third quarter. Novartis activated the Phase 2a/b clinical trial for VAV1-directed MGD MRT-6160 in Sjögren’s disease.
Enrollment and dosing for the GFORCE-1 study of MRT-8102 were completed in June, with the company now anticipating a readout in the second half of 2026.
Other timelines shifted as the company updated its IND submission for the cyclin E1-directed MGD program to 2027, moving it from the previously anticipated second half of 2026.
Cash, cash equivalents, restricted cash, and marketable securities totaled $626.0 million as of June 30, a decrease of $45.2 million from the $671.2 million reported on March 31.